In this episode, Ayesha talked about the launch of Amgen’s Amjevita, the first Humira biosimilar to hit the market. Amjevita received FDA approval in 2016 and after a legal settlement with Humira maker AbbVie, has finally reached market launch. AbbVie has been embroiled in legal battles over accusations of overpatenting and price hiking to block Humira biosimilar competition. Hear more about Amjevita and how 2023 is a big year for Humira biosimilars with over half a dozen more launching this year.
Ayesha also discussed new Alzheimer’s research from King’s College London that could lead to the development of a blood test for the early detection of the disease. The research found that certain biomarkers in the blood of patients with mild cognitive impairment (MCI), which some Alzheimer’s patients develop before being diagnosed with the disease, could predict the onset of Alzheimer’s up to 3.5 years before a clinical diagnosis is made. Learn more about the new research in this episode.
Read the full articles here:
Amgen’s Amjevita Enters Market as First Humira Biosimilar, But at Two Different Price Points
Early Detection of Alzheimer’s Disease: New Research Shows How a Blood Test Could Lead to Earlier Diagnosis
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a commentJOIN LOGIN